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Abstract Thepulmonarydistribution andclearance of 99mTc-labelledbeclomethasonedipropionate (Bec)--dilauroyl-
phosphatidylcholine (DLPC) were compared in nine asthmatic patients on inhaled steroids after a1-weekmedical treat-
ment period of long-acting b2-agonist formoterol.The patients were given formoterol 12 mg (OxisTurbuhaler
s) twice
daily in addition to their own regular inhaled corticosteroid therapy.Gamma lung scintigraphy and lung function tests
wereperformedbefore and after formoteroltreatment.Thebronchodilatingeffectofthe combined therapywas signifi-
cant: 1-week usage of inhaled formoterol enhanced peripheral lung deposition of beclomethasone liposome and thus
diminishedcentral/peripheraldepositionratio (C/Pratio).Allmeasuredlung functionvaluesexcept FEV1/FVC%improved
after themedicationperiod, although statistically significant levelswerenotreached.A systemicpositive connectionwas
seen between enhanced lung functions and greater lung deposition measured as AUC(0–24 h)/24.Beclomethasone lipo-
some formulationmaintained its long-lasting effect in connectionwith formoterol treatment. Atthe 4-hmeasurement,
76% of the liposome-entrapped radioactivity still remained in the lungs before and 75% after the medication period.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Formoterol is a highly potent and widely used b-2 selec-
tive adrenoceptor agonist combining the clinical advan-
tages of rapid onset of action with duration of action in
excess of 12h. In single-dose trials in adults,12 and 24mg
of formoterol dry powder provide a rapid onset of ac-
tion, 1^3min (1^3). Dose^response studies with formo-
terol aerosol and dry powder also demonstrate that a
substantial portion of the bronchodilating e¡ect ismain-
tained at12h after inhalation (4,5).Received11April 2002; accepted in revised form 29 April 2002
Correspondence should be addressed to:Dr Marisanna Saari,MD,
Department of Respiratory Medicine,Tampere University Hospital,
P.O.Box 2000, FIN-33521Tampere, Finland.Fax: +358 3 2483018;
E-mail: marisanna.saari@tays.¢Liposomes are one of the carrier systems widely in-
vestigated for pulmonary drug delivery. In our previous
studies, we have evaluated the pulmonary deposition
and clearance of inhaled beclomethasone dipropionate ^
dilauroylphosphatidylcholine (Bec^DLPC) liposomes in
healthy subject as well as in severe and mild asthmatic
patients (6,7).The clearance of 99mTc-bound Bec^DLPC
liposomes proved to be strikingly slow, attesting to the
fact that the liposome encapsulation of a drug can o¡er
sustainedrelease andprolonged drug action in lower air-
ways. Ithasbeen shown that forcedexpiratory volume in
1sec (FEV1) predicts to a high degree the penetration of
the peripheral zone of the lungs, where a lower FEV1 is
associated with less peripheral penetration (8).Our re-
sults con¢rmed the fact that Bec^DPLC liposomeswere
deposited more centrally in the lower airways of the
1000 RESPIRATORYMEDICINEpatients with severe asthma than of those having the
milder form of the disease.
Traditionally, if an asthmatic patient was poorly
controlled on a low or a moderate dose of inhaled corti-
costeroids (ICSs), increasing the dose was the accepted
treatment strategy. However, recent evidence
shows that combining b2-agonist with long-lasting e¡ect
(LABA) to the current ICS therapy produces a
greater improvement in asthma control compared with
increasing the dose of corticosteroid alone (9). b2-ago-
nists with long-acting properties are now well estab-
lished in the current guidelines as therapeutic option in
the management of asthma (10,11). However, to our
knowledge the e¡ect of long-acting b2-agonist on the
lungdepositionpatterns on inhaled steroidshas notbeen
studied.
In the present study, we addressed the question
whether inhaled dry powder formoterolmedication has
ane¡ecton theregional distribution andclearance of the
beclomethasone liposome in the lungs in asthmatics on
inhaled steroids. In addition, the changes in the lung func-
tion values were studied in connection with the lung de-
position studies.
MATERIALSANDMETHODS
Study design anddemographics
Nine adult non-smoking patients with chronic stable
asthmawere enrolled after being foundquali¢edbymed-
ical examination.Themean age of the subjects (¢vemen
and four women) was 48 years (range 25^70). All diag-
noses were based on clinical evaluation by the attending
pulmonary physician and ful¢lled the criteria de¢ned by
the AmericanThoracic Society with the addition of in-
crease in FEV1 415% following a bronchodilation test
(the inhalation of 200mg of salbutamol from the me-
tered-dose inhaler). All patients were asthmatic for at
least 1 year and required regular ICSs treatment. None
of the subjects had an exacerbation of their asthma or
an upper viral infection within the previous 4 weeks.
Moreover, patientswith signi¢cantpulmonaryor cardiac
diseasewere excluded.One of thepatients hadb-blocker
therapy to hypertension.
The study was designed as an open, before-and-after
trial. The patients were given a 1-week inhalation treat-
ment of formoterol 12mg twice daily (OxisTurbuhalers
AstraZeneca) in addition to their own regular anti-in-
£ammatory asthma medication. The gamma camera
study and spirometric measurements were conducted
before and after formoterol treatment.The patient was
urged to abstain from ca¡eine-containing beverages for
12h. All patients gavewritten informed consent prior to
the study,whichwas approvedby the Ethical Committee
of Tampere University Hospital.Liposome preparation and labelling of
Bec^DLPC liposomeswith 99mTc
Bec^DPLC liposomes were produced as previously de-
scribed by Waldrep, 1994 (12). Brie£y, 1mg Bec and
25mg DLPC were dissolved in 10-ml t-butanol. After
mixing, the Bec^DLPC solution was pipetted into glass
vials, rapidly frozen in dry ice^acetone and lyophilized
overnight to remove the organic solvent. The liposome
suspension was produced by adding ultra-pure water to
obtain a ¢nal drug concentration of 500mg/ml.The mix-
turewas stirred for 30min at 371C to allow hydration of
the liposomes.
The preformed Bec^DLPC liposomes were labelled
withTc in the presence of stannous chloride (SnCl
2
) as a
reducing agent. In the preparation of SnCl2 solution, it is
important to exclude thepossibility of oxidation of tin to
the non-reactive stannic form.Therefore, before dissol-
ving stannous chloride (67mg),100ml of sterile pyrogen-
freewater wasbubbled for 30minwith nitrogen in order
to expelmostof the oxygen.Onemilliliter of Tc pertech-
netate in sterile salineFwith a radioactivity of approxi-
mately 780MBq (21mCi) F was then added, and the
mixture (total volume 2.5ml) was shaken vigorously for
1min and left to react at room temperature for 30min.
Labelling e⁄ciency was determinedby paper chroma-
tography (ITCL-SG, prod. 61885, Gelman Sciences, Ann
Arbor, MI, U.S.A.). Free pertechnetate migrates to the
top of the paper, while liposomally entrapped material
remains at the application point. The labelling yield was
expressed as a percentage of the total amount of radio-
activity applied in the testing system. Aerosol character-
istics as well as assessment of 99mTc attachment to Bec^
DLPC liposome are described in more detail previously
by the author (6,7).
Corticosteroid^liposome delivery
The Tc-labelled Bec^DLPC suspension was delivered
from Aerotech II nebulizers (CIS-US, Bedford, MA,
U.S.A.) connected to an automatic, inhalation-synchro-
nized dosimeter (Spira Elektro 2, Respiratory Care Cen-
ter, HNmeenlinna, Finland). This dosimeter is triggered
by a very low inspiratory £ow rate with a threshold of
o2 l/min (13^15). The volume of each inhalation is dis-
played digitally, and the inhalation £ow rate is controlled
by a £ow indicator. A breath-actuated, variable-time cir-
cuit regulates air through a solenoid valve to a nebulizer,
set at a £ow rate of 10 l/min. The volume output of the
dosimeter with 0.5 s nebulization periods under these
operating conditions is 7ml/breath (SD 0.5) (13^15). In this
study, the dosimeter was set to commence nebulization
in the beginning of the inhalation after the patient had
inhaled a volume of10ml, with each inhalation lasting ap-
proximately 3.0 s.
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within the labelled liposomes (2.5ml) was placed in the
jet nebulizer. Subjects were instructed to place the
nebulizer tightly between their lips and inhale deeply.
With a noseclip and mouthpiece in place, the subject
controlled breathing with a £ow indicator (an LED
screen) so that the inspiratory £ow rate of each breath
reached but did not exceed 30 l/min. Inhalation
was followed by normal exhalation. Exhaled Bec-
liposomes were captured using a Hudson ¢lter. This
inspiration procedure was repeated 20 times according
to the subject’s own inspiratory cycle with no holding
of breath between inhalations. Nebulization was prac-
ticed by each subject with saline before the experiment
began.
In addition, spirometric measurements (Vitalograf,
Buckingham, U.K.) were performed before inhalation of
the Bec^DLPC suspension. At least three technically
correct maneuvers for maximal forced expiratory £ow-
volume curves were performed, and the curve with the
greatest sum of FEV1 and FVC was utilized in obtaining
data for the patient’s characteristics.
Gamma camerameasurements
Immediately after inhalation, anterior and posterior
views of the lungs and an anterior view of the orophar-
ynx were measured in a supine position by a large ¢eld
gamma camera (GE, CamStar XR/T, WI, U.S.A.)
equipped with a low-energy high-resolution parallel col-
limator. In order to evaluate themucociliary clearance of
the inhaled liposomes, scans were repeated 1, 2, 4 and
24h after the aerosol delivery. In addition, a posterior
ventilation scan was obtained after the liposome study
by inhaling noble gas 133Xe with a radioactive dose of
460MBq (12.5mCi). All imageswere stored on a compu-
ter (Hermes, Nuclear Diagnostics, HNgersten, Sweden)
for subsequent data analysis.
133Xe posterior images were used when regions of in-
terest (ROIs) were manually drawn around central and
peripheral (P) lung zones. ROIs were subsequently
superimposeduponeach liposome aerosol view, enabling
the quantity of aerosol dose in each of the zones to be
determined. Each image was manually aligned, i.e. each
lung view was shifted to adapt to the superimposed
ROIs. The lungs were divided into inner and outer re-
gions, with the central zone encompassing 33% (72%)
and the outer the remainder of the total lung area
(16,17). Lung distribution of the liposome aerosolwas de-
scribed as the ratio between central and peripheral lung
areas (C/P ratio). If the aerosol deposits uniformly
throughout the alveoli and peripheral airways,C/P ratio
will be less than 1.0. As particles are deposited in more
central airways, central aerosol activity will increase
and C/P ratio will rise. The total lung clearance curvewas described as a plot of the percentage of initial lung
burden vs. time after inhalation.
The number of counts and pixels in each ROI were
measured and saved on a ¢le in the Hermes computer.
Subsequently, the data were transferred via a local area
network to a personal computer and analyzed with a
program specially made for this study. Counts from the
anterior andposterior views of the lungswere combined
by taking geometricmeanvalues.The camera-to-patient
distancewas standardizedbyplacing the collimator close
to the chest for the anterior view andin contactwith the
imaging bed for the posterior view. Geometric mean
counts were corrected for the room’s background F
measured separately from each imageF and for radio-
active decay.
An approximate tissue absorption correctionwas car-
ried out by using the method described by Macey and
Marshall (18). Brie£y, individual transmission images of
each subject’s lung region were taken prior to the lipo-
some study using a £at radiation source and keeping the
imaging geometry similar both in transmission andventi-
lation scans.This transmission method was used to cor-
rect the individual emission counts recorded with the
gamma camera.
STATISTICALANALYSIS
Lung function variables weremeasured before and after
the treatment.Gamma camerameasurementswereper-
formed before and after the treatment at 0,1, 2, 4h and
24h after inhalation. The corresponding results for C/P
ratio and retention were summarized using the area un-
der curve (AUC(0^24h)/24) statistics. AUC(0^24h) was cal-
culated using the linear trapezoid rule.For lung function
variables, retention and AUC variables the within-pa-
tient changes were analyzed using the paired t-test and
were described as mean with 95% con¢dence intervals.
Spearman’s rank correlations were calculated to test
the associations between the within-patient changes in
lung functions vs.C/P ratio and retention.
RESULTS
The lung function test results before and after 1-week
formoterol treatment are shown in Tables 1 and 2. All
measured lung values except FEV1/FVC improved follow-
ing the medication period, although statistically signi¢-
cant levels were not reached.Themean improvement in
FEV1 was 0.15 l and FVC 0.18 l. Predicted lung values
(FVC%, FEV1%, FEV50%) increased approximately 4.0^
5.7%.
The regional pulmonary distribution of 99mTc-labelled
Bec^DLPC liposome in asthmatic patients before and
after formoterol treatment is shown in Fig.1.One-week
usage of inhaled formoterol enhanced peripheral lung
TABLE 1. Lung functionresults before and after1-week formoterol treatment
Mean SEM Min Max
FVC Before 4.18 0.5 2.56 7.53
After 4.36 0.54 2.63 8.26
FVC%pred Before 90.1 7.5 56 121
After 94.1 7.5 70 128
FEV1 Before 2.77 0.27 2.1 4.82
After 2.92 0.4 1.98 5.93
FEV1%pred Before 72.7 5.1 56 96
After 77.4 6.5 55 110
FEV1/FVC% Before 66.7 3.2 56 80
After 66.6 3.1 56 80
FEV50%pred Before 43.4 4.9 25 73
After 49.1 7 23 83
TABLE 2. The changes in lung functions during the1-week formoterol treatment
Change 95% CI
Mean SEM Lower Upper Pvalue
FVC 0.18 0.14 0.13 0.49 0.22
FVC%Pred 4 2.3 1.31 9.31 0.12
FEV1 0.15 0.13 0.16 0.46 0.3
FEV1%Pred 4.78 2.35 0.64 10.2 0.08
FEV1/FVC% 0.11 2.08 4.92 4.7 0.96
FEV50%pred 5.67 3.53 2.48 13.81 0.15
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FIG. 1. C/P ratios as a function of time in asthmatic patients
before and after1-week formoterol treatment.
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FIG. 2. The clearance of 99mTc from the lung of asthmatic
patients before and after formoterol treatment.
1002 RESPIRATORYMEDICINEdeposition of the beclomethasone liposome and thereby
diminishedcentral/peripheral depositionratio (C/P ratio).
Measured immediately after inhalation, C/P ratio was
0.87 (SEM=0.06) before formoterol treatment and 0.77
(SEM=0.04) afterwards. The positive e¡ect of the medi-
cation treatment retained throughout the 24h follow-
up period. The di¡erence in AUC(0^24h)/24 was statisti-
cally signi¢cant (P=0.011).Figure 2 shows the progressive clearance of inhaled
radiolabelled corticosteroid liposome in 24h follow-up.
However, no statistically signi¢cant di¡erences in reten-
tion curves before and after formoterol treatment were
detected, AUC(0^24h)/24 being 72.0 (SEM=2.1) and 73.6
(SEM=3.6), respectively. At the 4-h measurement, 76%
(SEM=2.5) of the liposome-entrapped radioactivity still
remained in the lungs before and 75% (SEM=4.2) after
TABLE 4. The correlations between changes in the lung functions in the retention and C/P ratio measured as AUC(0^24 h)/24
(Spearman correlations)
Change inretention AUC(0^24 h)/24 Change in C/PAUC(0^24 h)/24
r P-value r P-value
FEV1 0.4 0.29 0.17 0.67
FEV1/FVC% 0.44 0.24 0.26 0.5
FEV50%pred 0.13 0.73 0.52 0.15
TABLE 3. AUC(0^24 h)/24 for retention and C/P ratio before and after 1-week formoterol treatment in 9 asthmatics, and the
change betweenthese two occations
Before After Change Paired t-test
Mean SEM Mean SEM Mean 95%CI P-value
AUC(0^24 h)/24 for retention 71.95 2.06 73.61 3.64 1.66 4.43 to 7.75 0.548
AUC(0^24 h)/24 for C/P 0.708 0.025 0.646 0.03 0.062 0.106 to0.018 0.011
FORMOTEROL ANDLUNGDEPOSITION 1003the 1-week medication period. However, after 24h, the
minor di¡erence between retention of the corticoster-
oid liposomes was detected: the average dose being
63% before and 68% after the treatment.The di¡erence
between clearancerateswas 4.8% (95%CI:0.6 to10.2%,
P=0.075).
Tables 3 and 4 show the correlations between changes
in lung functions and changes in retention and C/P ratios
measured as AUC(0^24h)/24. A systematic positive con-
nection (r40) is seen due to the formoterol treatment,
i.e. greater peripheral lung deposition and enhanced lung
function values go hand in hand. A statistically signi¢cant
correlation was not, however, reached due to the low
number of subjects (n=9) participating in the study.
DISCUSSION
In the present study, we evaluated by means of radiola-
belling technique the deposition and clearance pattern
of inhaled glucocorticoid^liposome after inhaled dry
powder formoterol treatment. As previously shown,
short-acting b2-agonists are known to accelerate muco-
ciliary activity (19^23).Our interest was to observe mu-
cociliary clearance pattern of the beclomethasone
liposomes combined with the formoterol treatment. In
question is whether the long-lasting e¡ect of this formu-
lation ismaintained in connectionwith b2 adrenoceptor?
Therewere several reasons for us to include formoterol
in this study. First, formoterol is a widely used long-act-
ing b2-agonist which, when combined with inhaled glu-
cocorticoids, gives optimal control of asthma in most
patients. There is a strong scienti¢c rationale for thecombination of these two drug components (24). Sec-
ondly, formoterol has a unique pharmacological pro¢le
being both fast- and long-acting and thus enabling the
bene¢cial clinical outcome in 1-week medical treatment
period. In addition, there are only few reports published
about formoterol in connection with mucociliary clear-
ance and pulmonary deposition.
The bronchodilating e¡ect of formoterol is highly
documented in several previous studies (2,9,25,26); thus,
our results of the improved lung functions were antici-
pated.The dilation of the bronchial tree can also be de-
termined in a radioaerosol scintigraphy technique, which
demonstrates dynamically the pulmonary deposition
pattern of the inhaled radioactive aerosol. Isawa et al.
(27) performed lung cine-scintigraphy on ten patients
withbronchial asthma in remissionbefore and after inha-
lation of salbutamol, following intravenously adminis-
tered aminophylline. The bronchodilating e¡ect of the
combined treatment was clearly shown in the lungs by
more homogenous and less central deposition of the
radioaerosol; lung function data were also signi¢cantly
improved. In our current study,1-week formoterol treat-
ment combined with anti-in£ammatory medication sig-
ni¢cantly enhanced the peripheral penetration of
inhaled aerosols as well as improved lung functions in
asthmatic patients. Previously, we were able to show
how the regional lung deposition of the nebulized drugs
go hand inhandwith the lung function and the severityof
the asthma (6).Themagnitude of bronchial obstruction is
a determinant of aerosol distribution within the lung of
the patients with asthma, and the increased bronchial
obstruction enhances central airway deposition of in-
haled particles. The FEV1 predicts to a high degree the
1004 RESPIRATORYMEDICINEpenetration of the peripheral zone of the lungs, where
the lower FEV1 is associated with less peripheral pene-
tration.
The relationship between the clinical e¡ect of the
drug and its deposition site in the lung is poorly under-
stood.There are a number of studies describing the de-
position of inhaled drugs, less is known about the ideal
deposition sites. While the proportion of the central
and peripheral lung deposition can be determined by
radioaerosol technique, onlyminor evidence exists to in-
dicate which is more bene¢cial in terms of clinical out-
come. However, the importance of the magnitude of
the pulmonary deposition for therapeutic e¡ect of the
inhaled b2-agonist has been clearly demonstrated in a
study comparing administration of terbutaline viaTurbu-
haler and pMDI (28). Pulmonary deposition withTurbu-
haler was double of that achieved with the pMDI. The
increased deposition with Turbuhaler was re£ected as
bene¢cial clinical e¡ects, as measured by great improve-
ments in lung functions.The superior clinical e¡ectof the
combination therapymay partly be due to the broncho-
dilating e¡ect of the long-acting b2-agonist and thus pos-
sibly due to the increased deposition and greater
peripheral penetration of the inhaled anti-in£ammatory
drug. It also appears that LABA may potentiate the ef-
fects achieved with ICS alone in an additive or even in a
true synergymechanism (24).
Impairedmucociliary clearance in asthma hasbeen re-
ported in various studies (29^32). In our previous data,
the clearance of Bec^DLPC liposomes was faster
among patients with severe asthma than amongpatients
withmild asthma (6).Four hours after inhalation, a mean
of 82% of the total pulmonary dose was detected in the
lungs of the patients with mild asthma, while in those
with severe asthma the value was 69%. In healthy volun-
teers at 4-h measurement point, the retention was 87%
of the nominal dose (7).
It is not unreasonable to expect that b2-agonists im-
prove the mucociliary clearance mechanism in the lungs
because they are known to exhibit favorable e¡ects on
the ciliarybeats andmucus secretion invitro (19^21). Lind-
berg et al. (33) found formoterol to be a powerful, long-
acting ciliostimulant.The e¡ect of formoterol on muco-
ciliary function was investigated both in vitro and in vivo
with a photoelectric technique. Yates and associates
(34) using albuminmicrosperes labelledwith radioactive
technetium found nebulized short-acting b2-agonist fe-
noterol to increase mucociliary transport among
healthy non-smokers and smokers. A similar e¡ectof en-
hancedmucociliary clearance in the lungs of healthy non-
smokers after the administration of aerosolized isopro-
tenol has been veri¢ed (35).
Inpatientswith chronic bronchitis, the acceleration ef-
fect of b2 adrenoreceptor agonists in mucociliary clear-
ance has been shown.Terbutaline (5mg) orally has been
reported to increase mucociliary clearance in patientswith chronic bronchitis (36). Melloni et al. (37) demon-
strated in ten bronchitis patients that, after 6 days of
treatment using formoterol aerosol, the mucociliary
clearance increased by 46%.They concluded that the re-
sultwas linked to a better function ofmucociliary carpet
and notdue to the bronchodilation inducedby formoter-
ol because the penetration index did not change.
In our study, mucociliary transport patterns were de¢-
nitely abnormal in all patients before and after treatment.
However, very little in£uence of the treatment was seen
in clearancevalues, although e¡ectsweremore evident in
bronchodilation andperipheral deposition in the lungs. Si-
milar results documented by Isawa and associates (38)
also failed to show the acceleration of mucociliary clear-
ance in asthmatics after orally administered salbutamol.
Nordid the inhaled salbutamol followingintravenously ad-
ministered amoniphyllin change the clearance pattern,
although in both cases the bronchodilating e¡ect was sig-
ni¢cant (27).Perhaps the di¡erences in clearancepatterns
are due to the di¡erent in£ammation processes in asthma
and chronic bronchitis. In bronchitis, inwhichmost of the
patients are smokers or ex-smokers, ciliary beat fre-
quency is decreased and can be stimulated with b2 adre-
noceptor agonists. In asthma, the ciliary function is
paralyzed by bronchial epithelial in£ammation and can be
vitalized by anti-in£ammatory treatment as Agnew et al.
(39) were able to prove.
The possible advantages of inhaled liposome corticos-
teroids in asthma therapy have been concerned with
yielding fewer local and systemic side e¡ects from once-
a-day steroid inhalation. The great expectation for the
future has abated slightly duemainly to concerns of com-
mercial cost-e¡ectiveness.Recently, themain focus upon
liposomes in pulmonary delivery research is directed to
thegene therapy and anti-cancer liposomesFwithpro-
mising results.
We conclude that the beclomethasone liposome for-
mulation maintained its long-lasting e¡ect in connection
with formoterol treatmentin asthmatic patients. In com-
bination therapy, formoterol enhanced lung functions
andperipheral lung depositionwithout any signi¢cant ef-
fect onmucociliary escalator.
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